Risk factors for nausea and vomiting requiring the daily administration of 5-HT3 receptor antagonists in radiotherapy combined with temozolomide for high-grade glioma
Sign Up to like & getrecommendations! Published in 2024 at "Nagoya Journal of Medical Science"
DOI: 10.18999/nagjms.86.2.304
Abstract: ABSTRACT Radiotherapy combined with temozolomide (TMZ+RT) is the primary treatment for high-grade glioma. TMZ is classified as a moderate emetic risk agent and, thus, supportive care for nausea and vomiting is important. In Nagoya University… read more here.
Keywords: factors nausea; daily administration; ht3ra; risk factors ... See more keywords